This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

CX516

RespireRx Pharmaceuticals Inc.

Drug Names(s): AMPALEX, CX516 AMPAKINE

Description: CX516 is an AMPAKINE compound. These drugs interact in a specific manner with the AMPA receptor in the brain, lowering the amount of neurotransmitter required to generate a response, and increasing the magnitude of the response to any given amount of glutamate.

Deal Structure: In October 2000, Cortex entered intoa research collaboration and license agreement with Les Laboratoires Servier. The agreement, as amended in October 2002, allows Servier to develop and commercialize the Companys AMPAKINE technology in defined territories of Europe, Asia,the Middle East and certain South American countries as a treatment for memory impairment associated with aging and neurodegenerative diseases.

Partners: Les Laboratoires Servier


CX516 News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug